Arcus Biosciences, Inc. (RCUS) announced on Tuesday the outcomes from the first part of its ARC-10 study, which assessed the impact of combining Domvanalimab and Zimberelimab in comparison to the use of Zimberelimab alone or with chemotherapy.
This open-label, randomized study involved participants with newly diagnosed, locally advanced, or metastatic non-small cell lung cancer — both squamous and non-squamous types. These patients had a tumor proportion score for PD-L1 equal to 50 percent and did not exhibit any tumor genomic abnormalities or driver mutations.
Findings indicated that the combination of Domvanalimab and Zimberelimab significantly improved progression-free survival, overall survival, and the objective response rate when compared to Zimberelimab alone or chemotherapy. Furthermore, the rate of treatment-related adverse events that prompted treatment discontinuation was notably lower for the combination therapy as opposed to chemotherapy.
As of the latest report, Arcus's shares are trading at $15.32, experiencing a 1.54 percent decline on the New York Stock Exchange.